

Level 14 172 St Georges Terrace PERTH WA 6000 PO Box 7625 CLOISTERS SQUARE WA 6850 P: +61 8 9288 3388 Suite 606, Level 6 83 York Street SYDNEY NSW 2000 PO Box R1931 ROYAL EXCHANGE NSW 1225 P: +61 2 9024 9100



Market Watch March 2018

1 March 2018

marketwatch@amscot.com.au

Editor's Note

Fraudulent brokers and loan applications at NAB and the CBA-owned Aussie Home Loans are top of the agenda for examination when the Royal Commission into Misconduct in the Banking, Superannuation and Financial Services Industry kicks off later this month (13 March) in a packed week-long hearing in Melbourne.

Commissioner Kenneth Hayne will be diving straight into the quagmire of dodgy lending practises in the first week of public hearings. All four of the major banks, as well as Citi, are set to come under the blowtorch, with the commission publishing the specific case studies up for examination. Westpac and ANZ are also likely to come under fire over their car financing activities, Westpac will be in the spotlight for "unsuitable credit card limit increases", while Citi's imposition of international transaction fees will be looked at. Other areas to be examined in the opening round of royal commission hearings include home loans, add-on insurance, and account administration. Finally, and certainly not least, the commission expanded its case against CBA and will be examining claims by ASIC that the bank tried to rig a key interest rate – the bank bill swap rate - on six occasions.

All in all, it looks like the country's key players in the banking sector are due to face a torrid time. How this will impact share prices is uncertain, but we suggest that a public examination of how the industry has been conducting its business is unlikely to be a positive catalyst. At current price levels, Westpac (ASX: WBC) offers the most upside - relative to its IRESS consensus target price and IRESS consensus FY18E dividend yield - with a potential total return of ~16%.


Forecast total return for major ASX-listed financial stocks


Security	Name	Share	Target Price	Capital upside /	FY18E	FY18E DY	Total
		Price (A\$)	(A\$)	(downside) (%)	Dividend (A\$)	(%)	Return (%)
WBC	Westpac	30.93	33.83	9.4%	1.92	6.2%	15.6%
NAB	National Aust. Bank	30.09	32.64	8.5%	1.98	6.6%	15.1%
ANZ	ANZ Banking	28.78	31.23	8.5%	1.61	5.6%	14.1%
QBE	QBE Insurance	10.42	11.2	7.5%	0.47	4.5%	12.0%
AMP	AMP Limited	5.25	5.48	4.4%	0.29	5.5%	9.9%
SUN	Suncorp	13.55	14.06	3.8%	0.72	5.3%	9.1%
MQG	Macquarie Bank	102.13	104.84	2.7%	5.08	5.0%	7.6%
CBA	Commonwealth Bank	76.01	80.55	6.0%	0.96	1.3%	7.2%
BEN	Bendigo & Adelaide	11.55	11.21	-2.9%	0.70	6.1%	3.1%
BOQ	Bank of Queensland	12.91	12.45	-3.6%	0.80	6.2%	2.6%

Source: IRESS, compiled by State One Stockbroking Note: Share price and Target prices as at 26 February 2018



ASX 200: sector performance over past four weeks and year






Source: IRESS, compiled by State One Stockbroking


Commodities and AUDUSD: performance over past four weeks and year






Source: IRESS, compiled by State One Stockbroking

World Indices: performance over past four weeks and year (local currency)






Source: IRESS, compiled by State One Stockbroking



Commentary

- The FTSE/ASX 200 Index gained 0.1% in February with the Healthcare sector the best performer (by far) posting an 8.6% gain and the Energy sector the worst performer, posting a 5.7% loss.
- February was a broadly neutral to negative for commodities, with iron ore the exception posting a stand-out gain of 8.7%. The Australian dollar posted losses of 3.9% against the US\$, which helped offset a lackluster US\$ pricing environment.

ASX 200: top 25 and bottom 25 performing stocks over the past four weeks (% gain/loss)



Source: IRESS, compiled by State One Stockbroking

- **Top performer**: Sirtex Medical (ASX: SRX) appreciated by 49% following on the back of an end-January \$1.58bn takeover offer from Varian Medical Systems.
- Worst performer: IPH Limited (ASX: IPH) fell 38% on the back of disappointing interim results (1H FY18 net profit A\$19.7m, down 11%).



Month in review - events that caught our eye in February

getswift

Logistics software company GetSwift (ASX:GSW) facing class action from shareholders after share price collapse on concern over ASX queries on operational and disclosure issues. ...contagion spreads to other smaller players in the tech sector



North Korea sends high-level official delegation to the Winter Olympics in South Korea, which saw the two Koreas compete together in the women's ice-hockey event as a unified team.



Barnaby Joyce resigns as leader of the Deputy Prime Minister and leader of the Nationals Party after facing sustained pressure to quit following revelations of his affair with a former staffer.



Rio Tinto tips pay inflation after reporting a 69% increase in full-year profits and record dividend payout to shareholders.



Jacob Zuma resigns as President of South Africa following a power struggle within the ruling ANC party. Billionaire Cyril Ramaphosa elected as new leader.



Florida House committee responds to Parkland school shooting by approving bill to raise minimum age to buy a gun, and create program to arm teachers.



Worries over rising bond yields and inflationary pressures hit shares early in February with the US stock market suffering its worst week in two years.



One-time IT market darling Big Un (ASX:BIG) share price collapses over concern over undisclosed cash flow and financing concerns...reinforces concern over smaller players in the tech sector



Chinese Central Committee likely to formally abolish the term limit on presidential power, allowing the incumbent Xi Jinping to remain in office indefinitely. Move sparks fresh fears of role of China in the new world order.



Warnings and Disclosures

These Research products and their contents at all times remain the property of State One Stockbroking Ltd ("State One") and as such cannot be reprinted, distributed, copied, posted on the internet, in part or whole, without written prior approval from State One. The contents of this document constitute General Advice and have been prepared without taking account of your investment objectives, financial situation or needs. Because of that you should, before taking any action to acquire or deal in, or follow a recommendation (if any) in respect of any of the financial products or information mentioned in these documents, consult your own investment advisor to consider whether that is appropriate having regard to your own objectives, financial situation and needs. While State One believes information contained in these documents are based on information which is believed to be reliable, their accuracy and completeness are not quaranteed and no warranty of accuracy or reliability is given or implied and no responsibility for any loss or damage arising in any way for any representation, act or omission is accepted by State One or any officer, agent or employee of State One. If applicable, you should obtain the Product Disclosure Statement relating to any relevant financial product mentioned in this document (which contains full details of the terms and conditions of the relevant financial product) and consider it before making any decision about whether to acquire the financial product. The directors and associated persons of State One may have a long or short interest in the financial products discussed in these documents and they may earn brokerage, commissions, fees and advantages, pecuniary or otherwise, in connection with the making of a recommendation or dealing by a client in such financial products. Additionally, State One may earn fees due to having been appointed advisors to, or may be undertaking or about to commence research relating to any of the companies mentioned here.

Alan Hill Executive Chairman Phone: +61 8 9288 3388 ahill@stateone.com.au

Morris Levitzke Equities Advisor Phone: +61 8 9288 3315 mlevitzke@stateone.com.au

Dawn Chia
Business Development Manager
Phone: +61 8 9288 3336
Dawn.Chia@stateone.com.au

Ric Heydon Equities & Derivatives Advisor Phone: +61 8 9288 3307 rheydon@stateone.com.au

Graeme Johnson Equities & Derivatives Advisor Phone: +61 8 9288 3316 gjohnson@stateone.com.au

David Zhang Equities Advisor Phone: +61 2 9024 9130 dzhang@stateone.com.au Mark Sullivan Institutional Dealer Phone: +61 2 9024 9134 msullivan@stateone.com.au

Yitz Barber Equities Advisor Phone: +61 2 9024 9107 ybarber@stateone.com.au

David Brennan Senior Investment Analyst Phone: +61 2 9024 9142 dbrennan@stateone.com.au Thomas Tan Equities Advisor Phone: +61 2 9024 9131 ttan@stateone.com.au

Tammie Wong Equities Advisor Phone: +61 2 9024 9133 twonq@stateone.com.au